Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size

Nephron - Clinical Practice

Volumn 114, Issue 3, 2010, Pages

  Hirai, Takayuki ^a   Nakashima, Ayumu ^a,b   Takasugi, Norihisa ^a   Yorioka, Noriaki ^b  

^a Hakuai Hospital   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cinacalcet; Nodular hyperplasia; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCITRIOL; CALCIUM CARBONATE; CINACALCET; FALECALCITRIOL; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

ADULT; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MALE; ORGAN SIZE; PARATHYROID GLAND; PARATHYROID GLAND SIZE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; THERAPY RESISTANCE; TREATMENT OUTCOME;

FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; NAPHTHALENES; ORGAN SIZE; PARATHYROID GLANDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 70849116866     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000262301     Document Type: Article

References (24)

1. Moe SM, Drueke T: Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol 2008; 3(suppl 3):S127-130
2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G; Kidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953 (Pubitemid 43924257)
3. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1-201
4. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournie A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
5. Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S; KRN1493 study group: Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorous and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008; 23: 328-335
6. Komaba H, Fukagawa M, KRN1493 Study Group: Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Ther Apher Dial 2008; 12:S44-S49
7. Komaba H, Tanaka M, Fukagawa M: Treatment of kidney disease-mineral and bone disorder (CKD-MBD). Inten Med 2008; 47: 989-994
8. Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S: Long-term cinacalcet HCl treatment improving bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol 2008; 29: 230-236
9. Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S; KRN1493 Study Group: Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2008; 12: 117-125
10. Fukagawa M, Kurokawa K: Pathogenesis and medical treatment of secondary hyperparathyroidism. Semin Surg Oncol 1997; 13: 73-77
11. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K: Serial evaluation of parathyroid size by ultrasonography is another useful marker for longterm prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994; 68: 221-228
12. Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, Izumotani T, Yamakawa T, Imanishi Y, Shoji T, Inaba M, Nishizawa Y: Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003; 18: 2613-2621
13. Tominaga Y, Matsuoka S, Sato T, Uno N, Goto N, Katayama A, Haba T, Uchida K: Clinical features and hyperplastic pattern of parathyroid gland in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy. Ther Apher Dial 2007; 11: 266-273
14. Tominaga Y, Tanaka Y, Sato K, Nagasawa T, Takagi H: Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13: 78-86 (Pubitemid 27146980)
15. Tanaka M, Nakanishi S, Komaba H, Itoh K, Matsushita K, Fukagawa M: Association between long-term efficacy of cinacalcet and parathyroid gland volume in haemodialysis patients with secondary hyperparathyroidism. NDT Plus 2008; 1(suppl 3):iii49-iii53
16. De Francisco AL, Izquierdo M, Cunningham J, Pinera C, Palomar R, Fresnedo GF, Amado JA, Unzueta MG, Arias M: Calciummediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet. Nephrol Dial Transplant 2008; 23: 2895-2901
17. Payne RB, Little AJ, Williams RB, Milner JR: Interpretation of serum calcium in patients with abnormal serum proteins. BMJ 1973; 15: 643-646
18. Japanese Society for Dialysis Therapy: Guideline for the management of the secondary hyperparathyroidism in chronic dialysis patients. J Jpn Soc Dial Ther 2006; 39: 1435-1455
19. Taniguchi M, Tokumoto M, Tsuruya K, Hirakata H, Iida M: Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth. Nephrol Dial Transplant 2008; 23: 3662-3669
20. Malberti F, Corradi B, Cosci P, Calliada F, Marcelli D, Imbasciati E: Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidism. Am J Kidney Dis 1996; 28: 704-712
21. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-1721
22. Katoh N, Nakayama M, Shigematsu T, Yamamoto H, Sano K, Saito I, Nakano H, Kasai K, Kubo H, Sakai S, Kawaguchi Y, Hosoya T: Presence of sonographically detectable parathyroid glands can predict resistance to oral pulse-dose calcitriol treatment of secondary hyperparathyroidism. Am J Kidney Dis 2000; 35: 465-468
23. Colloton M, Shatzen E, Miller G, Stehman- Breen C, Wada M, Lacey D, Martin D: Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476
24. Meola M, Petrucci I, Barsotti G: Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009; 24: 982-989